Hepion Pharmaceuticals Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
HEPA$0.07-17.7%Stored close · as of Jul 8, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Revenues | $— | $— | $— | $— |
| Cost and expenses: | ||||
| Research and development | 2,762,709 | 8,518,520 | 12,438,956 | 30,196,848 |
| General and administrative | 1,695,550 | 2,146,045 | 5,705,468 | 7,842,512 |
| Total operating expenses | 4,458,259 | 10,664,565 | 18,144,424 | 38,039,360 |
| Loss from operations | (4,458,259) | (10,664,565) | (18,144,424) | (38,039,360) |
| Other income (expense): | ||||
| Interest income (expense) | (474,570) | (2,381) | (429,383) | (7,054) |
| Change in fair value of contingent consideration and derivative financial instruments | 66,881 | 140,000 | 6,526,633 | 180,000 |
| Inducement expense | — | — | (2,567,044) | — |
| Loss before income taxes | (4,865,948) | (10,526,946) | (14,614,218) | (37,866,414) |
| Income tax benefit | — | — | 2,969,252 | — |
| Net loss | $(4,865,948) | $(10,526,946) | $(11,644,966) | $(37,866,414) |
| Weighted-average common shares outstanding: | ||||
| Basic and diluted | 6,718,962 | 3,838,289 | 5,870,494 | 3,825,523 |
| Net loss per common share: (see Note 10) | ||||
| Basic and diluted | $(0.72) | $(2.74) | $(1.98) | $(9.90) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.